RecruitingNCT06238219

Management of Neuromuscular Blocking Agents and Their Antagonism

Clinical Practice Survey on the Management of Neuromuscular Blocking Agents and Their Antagonism During General Anesthesia


Sponsor

Erasme University Hospital

Enrollment

3,000 participants

Start Date

Apr 17, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Neuromuscular blocking agents (NMBA) are commonly used in clinical practice during general anesthesia to facilitate induction, intubation and surgery. Some studies have shown that their use can be deleterious if not codified. Recent recommendations concerning their use and antagonization were published in 2023. Research hypothesis: Using a single-center, retrospective practice study, we aim to analyze whether the 2023 ASA and ESAIC recommendations are being implemented regarding the use of neuromuscular blocking agents.


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • \- All patients undergoing surgery with use of neuromuscular blocking agents at our institution

Exclusion Criteria1

  • \- Incomplete electronic anesthesia record

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNeuromuscular Blocking Agent

Administration of any neuromuscular blocking agent for surgery under general anesthesia


Locations(1)

Hôpital Universitaire de Bruxelles - Hôpital erasme

Brussels, Belgium

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06238219


Related Trials